Substance / Medication

Zonisamide

Overview

Active Ingredient
zonisamide
RxNorm CUI
39998

Indications

Zonisamide capsules USP are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.

Labeler: Aurobindo Pharma LimitedUpdated: 2026-02-09T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

12 trials linked to this intervention

12
Total Trials
0
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy, tolerability, and safety of zonisamide in children with epileptic spasms: A systematic review and meta-analysis.
Panda Prateek Kumar, Sharawat Indar Kumar, Panda Pragnya et al. · Seizure · 2021
PMID: 34298456Meta-Analysis
Zonisamide add-on therapy for focal epilepsy.
Brigo Francesco, Lattanzi Simona, Igwe Stanley C et al. · Cochrane Database Syst Rev · 2020
PMID: 32715463Meta-AnalysisFull text (PMC)
Zonisamide add-on therapy for focal epilepsy.
Brigo Francesco, Lattanzi Simona, Igwe Stanley C et al. · Cochrane Database Syst Rev · 2018
PMID: 30335200Meta-AnalysisFull text (PMC)
Zonisamide for essential tremor.
Bruno Elisa, Nicoletti Alessandra, Filippini Graziella et al. · Cochrane Database Syst Rev · 2017
PMID: 28836659Meta-AnalysisFull text (PMC)
Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
Matsunaga Shinji, Kishi Taro, Iwata Nakao · J Alzheimers Dis · 2017
PMID: 28157097Meta-Analysis
Zonisamide for neuropathic pain in adults.
Moore R Andrew, Wiffen Philip J, Derry Sheena et al. · Cochrane Database Syst Rev · 2015
PMID: 25879104Meta-AnalysisFull text (PMC)
Zonisamide as a treatment for partial epileptic seizures: a systematic review.
Cox Joanna H, Seri Stefano, Cavanna Andrea E · Adv Ther · 2014
PMID: 24522856Meta-Analysis
Zonisamide add-on for drug-resistant partial epilepsy.
Carmichael Katie, Pulman Jennifer, Lakhan Shaheen Emmanuel et al. · Cochrane Database Syst Rev · 2013
PMID: 24353187Meta-Analysis
The adverse event profile of zonisamide: a meta-analysis.
Verrotti A, Loiacono G, Di Sabatino F et al. · Acta Neurol Scand · 2013
PMID: 23763367Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Zonisamide (substance)
SNOMED CT
125693002
UMLS CUI
C0078844
RxNorm CUI
39998
Labeler
Aurobindo Pharma Limited

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
12
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.